MCK·McKesson Corporation

MCK’s share price fell versus market gains, with analysts projecting EPS of $9.59 and revenue of $104.39 B for the quarter, and the company will report earnings on Aug 5, 2026. The dip comes amid a month‑to‑date gain of 4.17%, slightly behind the medical sector but ahead of the S&P 500, indicating that MCK is still outperforming the broader market but lagging peers. Leerink reduced its price target to $950 from $970, citing rising operating costs and competitive pressure, but kept an Outperform rating, suggesting a short‑term pullback but a bullish medium‑term stance. Zacks industry outlook places MCK among key pharma distributors, highlighting competitive dynamics that could pressure revenue streams and margins, with no specific guidance but a reminder that sector shifts may affect MCK’s performance. McKesson’s FY26 Impact Report details initiatives to improve patient outcomes, supply‑chain efficiency, and sustainable growth, which investors should monitor for alignment with financial results and regulatory compliance. The CEO’s sale of 8,463 shares under a pre‑arranged plan triggered a decline, underscoring sensitivity to insider activity, but the stock rebounded and the company’s 1‑year return of 14% and strong 5‑year performance suggest long‑term upside. Despite a 337.6% five‑year return, MCK remains undervalued per most valuation tests, with thin operating margins and execution risk potentially limiting upside, so investors should watch for capital return announcements and peer performance trends. The appointment of a new Chief Strategy Officer and revised growth targets signals a strategic shift, so traders should assess how the new strategy chief’s plans align with the updated guidance. Given the recent insider sale and the price target cut, the next 1–10 trading days will likely see volatility around the earnings release, so watch for any cost‑control initiatives and updates to the company’s outlook.